EMA changes tune, endorses Eisai and Biogen's Leqembi in restricted Alzheimer's population
Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | Upon reexamination, the EMA has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi.
Deep-pocketed investors have adopted a bearish approach towards Biogen BIIB, and it's something market players shouldn't ...
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...
Wolfe Research analyst Alexandria Hammond initiated coverage of Biogen (BIIB) with a Peer Perform rating. With a legacy portfolio that ...
Shares of Biogen Inc. BIIB slid 1.48% to $165.79 Wednesday, on what proved to be an all-around favorable trading session ...
Leqembi’s sales continue to be underwhelming, according to analysts, who contend the companies’ Alzheimer’s disease therapy ...
Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary ...
Citi analyst Geoff Meacham initiated coverage of Biogen (BIIB) with a Neutral rating and $190 price target The company’s strategy to offset core franchise erosion has been to develop assets with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback